Bian et al. reported a 31-year-old male patient was diagnosed as stage IV intrahepatic CCA with PIK3CA mutation (E545G), which may result in activating mTOR pathway so patient received everolimus and achieved partial response (PR) after 2-month everolimus and at least 6-month PFS [106]. Here, PIK3CA is linked to cholangiocarcinoma.